Quick answer
TB-500 purity testing means two things: reversed-phase HPLC to see how much of the sample is one species, and mass spectrometry to prove that species is the thymosin β4–derived sequence on the label.
- Reference molecule: full-length thymosin β4 is a 43-residue, N-acetylated peptide of about 4.96 kDa; some sources use "TB-500" for shorter fragments, so the CoA must state which
- HPLC: separates truncated and deletion sequences from the target; purity is main-peak share of total area
- Mass spectrometry: independent identity check that retention time alone cannot give
- Typical oxidation flag: a +16 Da species points to methionine sulfoxide
- Product: the TB-500 10 mg research vial is listed at ≥98% HPLC; batch records are on the CoA page
- Research use: For laboratory research use only; not for human consumption.
What "TB-500" refers to
For laboratory research use only; not for human consumption.
A vial labeled TB-500 is only as useful to a research protocol as the analytical data behind it. Because the peptide is defined by a specific amino-acid sequence derived from thymosin β4, verifying that a given lot actually matches that sequence — and contains little else — is the entire basis of meaningful purity testing. Skipping this step doesn't just risk wasted material; it risks building an entire dataset on a sample that was never what the label claimed.
The name itself needs care. Thymosin β4 is a 43-residue peptide, N-terminally acetylated, of roughly 4.96 kDa. TB-500 is commonly described as a synthetic version of it, and the actin-binding region that most mechanistic work centers on is the short LKKTETQ stretch near residues 17–23. Some suppliers and discussions use the name for the full-length molecule and others for fragments containing that region, and the two have very different masses. The product listing for the TB-500 vial gives a molecular formula and a sequence field, and the certificate of analysis is the document that should state, unambiguously, which molecule was synthesized and measured. Mechanistic background is in the TB-500 research overview.
| Candidate material | Length | Approximate mass | What a CoA should show |
|---|---|---|---|
| Full-length thymosin β4 (N-acetylated) | 43 residues | About 4,963 Da | Observed mass matching the full-length value |
| Same sequence without the N-terminal acetyl | 43 residues | About 42 Da lower | A mass shift of roughly −42 Da flags an unacetylated product |
| Fragment containing the actin-binding region | Short (tens of residues or fewer) | Far below 4.96 kDa | Sequence stated explicitly, with a matching mass |
Reversed-phase HPLC
High-performance liquid chromatography separates a peptide sample by hydrophobicity, resolving the intended TB-500 sequence from truncated fragments, deletion sequences, and other synthesis byproducts that can arise during solid-phase synthesis. Purity is then reported as the target peak's share of total peak area — background on how to interpret that figure is at understanding HPLC purity analysis.
Length matters here. In stepwise solid-phase synthesis, each coupling cycle is slightly less than 100% efficient, so a 43-residue chain accumulates many closely related failure sequences: peptides missing one residue, peptides that stopped early, and peptides with a side-chain protecting group not fully removed. These are chemically similar to the target and elute close to it, which is why a shallow gradient and a wide-pore column are usually needed to resolve them. A very steep gradient can merge several of them into one apparently clean peak.
What to look for in the trace
- A main peak that is symmetrical, with no leading shoulder (often a deletion product) or trailing shoulder (often a modified form).
- Minor peaks integrated separately and listed, not folded into baseline.
- Stated column, mobile phases, gradient, temperature and detection wavelength (typically 214–220 nm for peptide bonds).
Confirming identity with mass spectrometry
HPLC purity alone does not confirm that the dominant peak is actually TB-500 rather than a similarly hydrophobic contaminant, which is why mass spectrometry is run alongside it. Measuring the peptide's mass and comparing it against the expected value for the stated TB-500 sequence gives an independent confirmation of identity that HPLC retention time alone cannot provide, since two different peptides can occasionally elute at similar times. See HPLC vs. mass spectrometry for how the two techniques complement each other.
A peptide near 5 kDa carries several charges in electrospray ionization, so the raw spectrum shows a series of peaks that software deconvolutes to a single neutral mass. A credible report lists the theoretical and observed masses next to each other. Because thymosin β4 is rich in lysine, glutamate and aspartate, it also forms sodium and potassium adducts readily; small satellite peaks at +22 and +38 Da on the main species are usually adducts rather than impurities.
| Mass observation (vs. target) | Typical explanation |
|---|---|
| +16 Da | Methionine oxidized to sulfoxide (the sequence contains one methionine) |
| −42 Da | Missing N-terminal acetyl group |
| +1 Da | Deamidation of an asparagine or glutamine, or isotope-envelope effects at this mass |
| Lower by one residue mass | Deletion sequence from an incomplete coupling |
| +22 / +38 Da | Sodium / potassium adduct (instrument artifact, not sample impurity) |
Why both tests matter for actin-binding research
TB-500 research typically depends on subtle, concentration-sensitive cellular responses tied to actin dynamics, which makes it especially vulnerable to confounding from unverified material — a sample contaminated with unrelated peptide fragments or synthesis byproducts can produce migration or angiogenesis assay results that have nothing to do with the compound actually being studied. Because the effect sizes researchers look for in these assays are often modest, even a small fraction of contaminating peptide can meaningfully shift an outcome, which is why purity thresholds in this space tend to be set conservatively rather than treated as a formality.
A second reason is oxidation. Methionine sulfoxide is a common and easily missed modification; a lot that has been stored poorly can drift toward it over time, and an assay that depends on a structured peptide–actin interaction can be sensitive to such changes. Running mass spectrometry on the working solution, not only on the original lot, is the direct way to see it.
Net peptide content and working concentration
An area-percent figure says what fraction of the peptide-like material is the target; it does not say how much of the powder is peptide. A highly charged peptide such as this one holds counter-ions and water, so the labeled vial mass overstates the peptide mass to some extent. When a cell-based assay depends on a precise molar concentration, ask whether net peptide content has been determined and apply it as a correction. The peptide calculator converts vial mass and diluent volume into mg/mL, and you can then convert to molar concentration using the molecular weight that the CoA states.
Documentation researchers should expect
Reputable suppliers issue a lot-specific certificate of analysis for every batch of TB-500, ideally corroborated by independent third-party lab results rather than in-house claims alone; third-party testing explained covers the distinction. A usable report includes:
- A lot or batch identifier that matches the vial
- The HPLC chromatogram and its method conditions
- Observed and theoretical mass, with the sequence or fragment named
- Test date and the laboratory that ran the analysis
TB-500 is also supplied as part of the BPC-157 + TB-500 research stack. A blend needs its own documentation, because each constituent has to be identified and quantified separately; the issues are discussed in BPC-157 + TB-500 third-party testing. For how TB-500 compares with its frequent companion peptide in the literature, see BPC-157 vs. TB-500.
Handling a verified lot
The listing for the TB-500 vial describes lyophilized powder in a sealed clear glass research vial, with storage at 2–8 °C and −20 °C for the long term, protected from heat, moisture and light. Those conditions matter analytically as well as practically: moisture and warmth accelerate oxidation and deamidation, and once in solution the peptide is considerably less stable than the dry cake. Aliquot working solutions, record the preparation date, and keep a retained sealed sample for re-analysis if a result looks unexpected. More general guidance is in storing research peptides. If you are comparing sources, where to buy TB-500 explains the documentation to ask for.
Frequently asked questions
What is TB-500 in analytical terms?
It is described as a synthetic version of thymosin β4, a 43-residue N-acetylated peptide of about 4.96 kDa. Some sources apply the name to shorter fragments. The CoA should name the exact sequence and give a mass that matches it.
Is HPLC purity enough to confirm a TB-500 lot?
No. HPLC shows how much of the sample is one species, but not what that species is. Mass spectrometry is needed to confirm that the main peak is the stated sequence.
What does a +16 Da peak mean?
Usually oxidation of methionine to methionine sulfoxide. It can arise during storage or handling, so it is worth checking on working solutions as well as on the original lot.
Why can a long peptide like this contain so many related impurities?
Each coupling step in solid-phase synthesis is slightly under 100% efficient, so a chain of this length accumulates deletion and truncation products that elute close to the target.
Do I need a separate certificate for the BPC-157 + TB-500 stack?
Yes. A blend contains two compounds, and the documentation should identify and quantify each. See the stack product page and the batch records on the CoA page.
Does purity percentage tell me how much peptide is in the vial?
No. Counter-ions and water add weight without adding peptide. Net peptide content, where reported, is the figure to use for exact molar concentrations.
How should I store TB-500 to keep the verified purity?
The product page specifies refrigeration at 2–8 °C, or −20 °C for the long term, away from heat, moisture and light. Aliquot after reconstitution to avoid repeated freeze-thaw cycles.
Research Use Only. For laboratory research use only; not for human consumption. Supplied strictly for laboratory research and development, not for human or veterinary use, and not for diagnostic purposes. This article is research education, not usage guidance.
References
- TB-500 research overview (V8 Peptides)
- Understanding HPLC purity (V8 Peptides)
- HPLC vs. mass spectrometry (V8 Peptides)
- How to read a CoA (V8 Peptides)
- BPC-157 + TB-500 third-party testing (V8 Peptides)
- TB-500 product specification (V8 Peptides)